Market Cap 27.97M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio -0.37
Volume 14,300
Avg Vol 45,688
Day's Range N/A - N/A
Shares Out 4.04M
Stochastic %K 9%
Beta 0.74
Analysts Sell
Price Target $250.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
MaxMiamiFl
MaxMiamiFl Jul. 31 at 3:26 PM
$FGEN That Wett bastard needs to wake up. SELL the company to ASSTRAZENECA!!
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Jul. 31 at 2:11 PM
$FGEN The trading volumes are small, there is little selling and little buying. It is not clear whether this is a good thing or a bad thing. But I tend to think that people are holding stocks...
0 · Reply
MarketWarfare
MarketWarfare Jul. 31 at 1:59 PM
$FGEN no news is bad news, Thane F-face Wettig. We are still unhappy about the reverse split. Provide an update to shareholders, you lazy shitstain.
1 · Reply
Dodo71
Dodo71 Jul. 27 at 6:19 PM
$FGEN yesssddd
0 · Reply
Dodo71
Dodo71 Jul. 27 at 6:11 PM
$FGEN https://clinicaltrials.gov/study/NCT06842498?term=Cd46&rank=1
0 · Reply
Kalns
Kalns Jul. 27 at 1:42 PM
$FGEN www.become-saved.com
1 · Reply
Value10
Value10 Jul. 24 at 10:34 PM
$FGEN Did anyone see where it appears the China drug was finally approved for Chemo patients in China? I am not sure if this is accurate? But I saw a posting of it? If so, do you believe that FGEN receives the $10M milestone??? If the $10M milestone comes in, that should give FGEN a few more months of breathing room… to wait for the China Sale. If drug is indeed approved, it has taken 2 years waiting for that approval from China!!!
1 · Reply
MarketWarfare
MarketWarfare Jul. 24 at 4:09 PM
$FGEN the do-nothing, say-nothing strategy of Thane Wettig is obviously not helping shareholders.
1 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 23 at 8:23 PM
$FGEN Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 million Transaction expected to close in 3Q 2025
0 · Reply
MarketWarfare
MarketWarfare Jul. 23 at 2:32 PM
$FGEN if chemotherapy-induced anemia (CIA) approval occurs in China, FibroGen (FGEN) is indeed entitled to a milestone payment under its agreement with AstraZeneca. According to FibroGen’s Q1 2024 report, they would receive a $10 million milestone upon approval of roxadustat for CIA in China. This obligation stems from the licensing agreement tied to AstraZeneca’s acquisition of the FibroGen China unit, where AstraZeneca agreed to these regulatory milestones as part of the deal . So, if and when CIA approval is granted by Chinese regulators, FibroGen should receive the payment.
2 · Reply
Latest News on FGEN
FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 7 weeks ago

FibroGen Announces 1-for-25 Reverse Stock Split


FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:31 PM EDT - 2 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript


FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 3 months ago

FibroGen to Report First Quarter 2025 Financial Results


FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:18 PM EDT - 4 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript


FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 8 months ago

FibroGen Appoints David DeLucia as Chief Financial Officer


FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 9 months ago

FibroGen Reports Third Quarter 2024 Financial Results


FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 9 months ago

FibroGen to Report Third Quarter 2024 Financial Results


FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript


FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results


FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences


FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript


FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results


FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results


FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer


FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:44 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript


FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 1 year ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN


FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:30 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript


FibroGen Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 4:01 PM EST - 1 year ago

FibroGen Reports Third Quarter 2023 Financial Results


FibroGen to Report Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 1 year ago

FibroGen to Report Third Quarter 2023 Financial Results


MaxMiamiFl
MaxMiamiFl Jul. 31 at 3:26 PM
$FGEN That Wett bastard needs to wake up. SELL the company to ASSTRAZENECA!!
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Jul. 31 at 2:11 PM
$FGEN The trading volumes are small, there is little selling and little buying. It is not clear whether this is a good thing or a bad thing. But I tend to think that people are holding stocks...
0 · Reply
MarketWarfare
MarketWarfare Jul. 31 at 1:59 PM
$FGEN no news is bad news, Thane F-face Wettig. We are still unhappy about the reverse split. Provide an update to shareholders, you lazy shitstain.
1 · Reply
Dodo71
Dodo71 Jul. 27 at 6:19 PM
$FGEN yesssddd
0 · Reply
Dodo71
Dodo71 Jul. 27 at 6:11 PM
$FGEN https://clinicaltrials.gov/study/NCT06842498?term=Cd46&rank=1
0 · Reply
Kalns
Kalns Jul. 27 at 1:42 PM
$FGEN www.become-saved.com
1 · Reply
Value10
Value10 Jul. 24 at 10:34 PM
$FGEN Did anyone see where it appears the China drug was finally approved for Chemo patients in China? I am not sure if this is accurate? But I saw a posting of it? If so, do you believe that FGEN receives the $10M milestone??? If the $10M milestone comes in, that should give FGEN a few more months of breathing room… to wait for the China Sale. If drug is indeed approved, it has taken 2 years waiting for that approval from China!!!
1 · Reply
MarketWarfare
MarketWarfare Jul. 24 at 4:09 PM
$FGEN the do-nothing, say-nothing strategy of Thane Wettig is obviously not helping shareholders.
1 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 23 at 8:23 PM
$FGEN Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 million Transaction expected to close in 3Q 2025
0 · Reply
MarketWarfare
MarketWarfare Jul. 23 at 2:32 PM
$FGEN if chemotherapy-induced anemia (CIA) approval occurs in China, FibroGen (FGEN) is indeed entitled to a milestone payment under its agreement with AstraZeneca. According to FibroGen’s Q1 2024 report, they would receive a $10 million milestone upon approval of roxadustat for CIA in China. This obligation stems from the licensing agreement tied to AstraZeneca’s acquisition of the FibroGen China unit, where AstraZeneca agreed to these regulatory milestones as part of the deal . So, if and when CIA approval is granted by Chinese regulators, FibroGen should receive the payment.
2 · Reply
MarketWarfare
MarketWarfare Jul. 23 at 11:46 AM
$FGEN why the gap down in pre market? 5% drop Bid: 7.30 Ask: 7.50 Literally every other POS in this market goes up except this stock.
0 · Reply
mjtwins16
mjtwins16 Jul. 23 at 11:31 AM
$FGEN cia approval?
3 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 22 at 6:37 PM
$FGEN when??????????????
1 · Reply
MarketWarfare
MarketWarfare Jul. 21 at 2:29 PM
$FGEN after the China deal closes and MS is paid off, FGEN should have 135-140M in cash. That's $35 per share in cash alone. Does the market think that little of Thane Fuckface Wettig and his vision? If so, it's time for him to go...
3 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 18 at 7:29 PM
$FGEN The average one-year price target for FibroGen (FGEN) is $250.00, according to Ticker Nerd. This target is based on a consensus of 10 Wall Street analysts. The current trading price of FGEN is $7.69. Therefore, the median forecast implies a 3,151.0% upside.
0 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 18 at 2:49 PM
$FGEN the friday flush
0 · Reply
deerix
deerix Jul. 18 at 12:57 PM
$FGEN 44% since post and for didn't buy. Oh well haha. Sometimes I want things too cheap and thus miss out
0 · Reply
StockScanners
StockScanners Jul. 18 at 2:15 AM
$FGEN Reached 8.26, now thats a run, be ready for next idea team
0 · Reply
TwongStocks
TwongStocks Jul. 17 at 9:02 PM
One month post-RS recap. All three with low daily volume since the RS. However, all are currently trading higher than they were on Jun 17. $RAPT 1:8 RS on Jun 17, closed $7.84 Daily volume over the past 30 days only exceeded 200k twice. From Jun 17 - Jul 14 closing price range was $7.33-$9.73. On July 15, saw its highest volume 755k shares & its highest price $11.94. Today closed $10.23, up 30.48% from RS close. $SNSE 1:20 RS on Jun 17, closed $6.55 Highest volume was Jun 18 at 44k, but most days were less than 10k. Lowest price was $5.86, on Jun 17. Managed to trade above that since then. Reached $9.27 on Jul 8. Today closed $8.02, up 22.44% from RS close. $FGEN 1:25 RS on Jun 17, closed $5.88. On the day of the RS, 155k volume. Since then, most days daily volume was below 100k. Peak vol 227k Jul 10. Jun 17 - Jul 8, closed in the $5S. Lowest price was $4.85 on Jun 30. Since Jul 9, managed to rise and close over $7. Today closed $8.07, up 37.24% from RS close.
0 · Reply
Value10
Value10 Jul. 17 at 6:53 PM
$FGEN Remember, while hitting $8.00 today sounds good… that is only approximately $0.32 cents per share pre-RS… which is still SO UNDERVALUED at $0.32 cents. If China-Sale is approved… this thing will be at $1.00 pre-RS or higher. So, let’s remember that this is over-sold into the dirt… it should easily be at $25 to $35 a share. Maybe within eight weeks? $8.00 is still WAY CHEAP!
2 · Reply
MarketWarfare
MarketWarfare Jul. 17 at 6:36 PM
$FGEN I would agree. Get the share price as high as possible under the radar, then drop news that pops this 200-500% overnight. Lots of tiny biotechs popping like that recently.
1 · Reply
DanilaMaster
DanilaMaster Jul. 17 at 5:44 PM
$FGEN can we slowly and unnoticed climb all the way to $25 :-)
1 · Reply